BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poovorawan K, Pan-Ngum W, White LJ, Soonthornworasiri N, Wilairatana P, Wasitthankasem R, Tangkijvanich P, Poovorawan Y. Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era. PLoS One 2016;11:e0163095. [PMID: 27631382 DOI: 10.1371/journal.pone.0163095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thaneskongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Suwanpatoomlerd S, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence. PLoS One 2017;12:e0177022. [PMID: 28475637 DOI: 10.1371/journal.pone.0177022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
2 Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018;47:1278-1287. [PMID: 29516535 DOI: 10.1111/apt.14593] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
3 Wasitthankasem R, Pimsingh N, Treesun K, Posuwan N, Vichaiwattana P, Auphimai C, Thongpan I, Tongsima S, Vongpunsawad S, Poovorawan Y. Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: Burden Assessment toward HCV Elimination. Am J Trop Med Hyg 2020;103:175-82. [PMID: 32394881 DOI: 10.4269/ajtmh.19-0817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Posuwan N, Wanlapakorn N, Sintusek P, Wasitthankasem R, Poovorawan K, Vongpunsawad S, Poovorawan Y. Towards the elimination of viral hepatitis in Thailand by the year 2030. J Virus Erad 2020;6:100003. [PMID: 33251021 DOI: 10.1016/j.jve.2020.100003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Poovorawan Y. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study. PLoS One 2018;13:e0196301. [PMID: 29689073 DOI: 10.1371/journal.pone.0196301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
6 Phisalprapa P, Tanwandee T, Neo BL, Singh S. Knowledge, attitude, and behaviors toward liver health and viral hepatitis-related liver diseases in Thailand. Medicine (Baltimore) 2021;100:e28308. [PMID: 34941122 DOI: 10.1097/MD.0000000000028308] [Reference Citation Analysis]